ABIONYX Pharma receives €8.7 million in support for its sepsis project

ABIONYX Pharma has been selected among the winners of the “i-Démo” call for projects of the France 2030 plan. The company benefits from financial support from the State of 8.7 million euros, aimed at developing a treatment for sepsis, the third leading cause of death worldwide. The biomedicine CER-001, based on apoA-I, has anti-inflammatory properties and could revolutionize the management of this severe infection.

The company's project is based on a unique recombinant protein and aims to offer an effective therapeutic solution to the immune challenges of sepsis. ABIONYX Pharma intends to confirm, through clinical trials, its potential to reduce mortality linked to this condition.